How Nordic Nanovector Stepped Back From The Abyss With APIM Merger

Picked Fellow Norwegian Firm After Multiple Talks

 
• By Kevin Grogan

Five months after its lead drug Betalutin failed for follicular lymphoma, Nordic Nanovector has secured its future by teaming up with Trondheim-based APIM and gained access to its mid-stage investigational therapy for ovarian cancer, sarcoma and glioblastoma.

Lifeline
Nordic Nanovector thrown a lifeline • Source: Shutterstock

Having weighed up 25 possible M&A opportunities, troubled Nordic Nanovector ASA has been explaining why it decided to plump for a merger with fellow Norway-headquartered biotech APIM Therapeutics AS .

Nordic Nanovector's woes began in July with the discontinuation of the Phase IIb PARADIGME trial in July that was evaluating the anti-CD37 radioimmunoconjugate candidate Betalutin (177Lu lilotomab satetraxetan) in patients...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business